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Abstract
Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at
relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought
to act by targeting tumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic che-
motherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alterna-
tive for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology
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is still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology
and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have
limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on
Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marseille, France, and brought
together clinicians, basic scientists, physician-scientists, trainees, and students from all around the world. The main
aim of this international meeting was to provide a unique forum to 1) reflect on the major advances that have been
made in this field of research since its creation, 2) communicate results from the most recent clinical trials and pre-
clinical studies, 3) discuss the current and future challenges of the field, and 4) set forth a solid framework for future
collaborative biologic and clinical studies. The present report documents the main preclinical and clinical data that
were presented in the keynote and best abstract sessions and delivers the key messages from the meeting.
Translational Oncology (2011) 4, 203–211
Introduction
Most conventional chemotherapy regimens are based on the cyclic
administration of anticancer drugs near or at the maximum tolerated
dose (MTD), alternating with long periods of drug-free break to al-
low patient recovery from toxic adverse effects. This strategy has led
to disease control in a significant number of both adult and pediatric
cancer patients but is associated with significant short-term and long-
term complications. In addition, despite impressive initial tumor re-
gression or even remission, regrowth and recurrence are common
events in metastatic cancer and high-risk tumors. Although the effec-
tiveness and rationale of MTD-based chemotherapy regimens and
dose-escalation strategies has been questioned for many years, especially
in patient populations with poor-prognosis tumors [1], convincing
preclinical data were needed to validate the potential of alternative
schedules of drug administration. Such groundbreaking preclinical
studies were published 10 years ago by Browder et al. [2] from Judah
Folkman’s laboratory and confirmed in Robert Kerbel’s laboratory
[3]. Using transplantable tumors [2] and xenograft models [3], both
teams demonstrated that the frequent administration of low-dose che-
motherapy could exert potent anticancer effects, through inhibition of
angiogenesis. The first study further showed that antiangiogenic sched-
uling of cyclophosphamide administration was more effective than
conventional schedule and could overcome drug resistance [2], whereas
the second study revealed a synergism between continuous treatment
with low-dose vinblastine and anti–vascular endothelial growth factor
(VEGF) receptor therapy [3]. After these landmark articles, Hanahan
et al. [4] coined the termmetronomic to the treatment regimens defined
by the frequent, repetitive administration of chemotherapeutic drugs
at low doses, with no prolonged drug-free break.
As reviewed recently [5], metronomic chemotherapy has gained
greater attention in the clinic and showed promising results in phase 2
clinical studies for the treatment of adult patients with various types
of advanced and/or refractory tumors such as metastatic breast and
prostate cancers. Several phase 3 clinical trials are also currently under-
way (www.clinicaltrials.gov) including for the treatment of metastatic
(NCT01131195) and triple-negative (NCT01112826) breast cancer
and advanced colorectal carcinoma (NCT00442637). In pediatric
oncology, however, as for other antiangiogenic strategies, the clinical
development of metronomic chemotherapy is still in its early stage
[6]. While the mechanisms of action of metronomic chemotherapy
have only recently been investigated, the use of low-dose oral chemo-
therapy, even after administration of MTD doses of the same drug,
has been around for many decades in both adult [7] and pediatric pa-
tients [8], with excellent radiographic response rates. Likewise, the long-
term administration of oral agents in themaintenance phase of leukemia
may function through a similar mechanism [9,10].
On March 18 and 19, 2010, the 2nd International Workshop on
Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncol-
ogy was held in Marseille, France. This workshop brought together
clinicians (pediatric oncologists, radiologists and pharmacists), basic
scientists (cell biologists, biochemists, pharmacologists, and mathe-
maticians), physician-scientists, trainees, and students from Europe,
North and South America, Africa, Israel, and Australia. The specific
objectives of this international meeting, which included 16 keynote
addresses, 8 oral presentations selected from the best submitted ab-
stracts, and 3 “tumor-specific” working group sessions (i.e., brain tu-
mors, sarcomas, and neuroblastoma), were to:
i) reflect on the major advances that have been made in this
field of research since its inception;
ii) increase awareness and credibility of metronomic treatments
by communicating results from the most recent clinical trials
and preclinical studies;
iii) discuss the current and future challenges of the field, which
include overcoming empiricism in protocol design, identifying
reliable biomarkers and defining appropriate treatment end
points for clinical trials; and
iv) set forth a solid framework for future research and design in-
novative protocols of metronomic treatments to be investigated
in multicentered clinical trials.
The present report documents the main preclinical and clinical
data that were presented in the keynote and best abstract sessions,
summarizes the results of the tumor-specific working groups, high-
lights the future challenges of the field, and delivers the key messages
from the meeting.
Key Clinical Data Supporting the Development of
Metronomic Treatments in Pediatric Oncology
After the publication in 2000 of the two pioneering studies that led to
the emergence of this field of cancer research [2,3], the safety and effi-
cacy of metronomic scheduling of chemotherapy has been investigated
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and demonstrated in several clinical trials in adult cancer patients with
advanced and/or refractory tumors (reviewed in Pasquier et al. [5]). De-
spite a first pilot study published by Sterba et al. in 2002 [11], clinical
studies performed in pediatric cancer patients currently represent less
than 10% of all refereed publications on metronomic treatments.
The 2nd InternationalWorkshop onMetronomic and Anti-Angiogenic
Chemotherapy in Paediatric Oncology provided a much-needed oppor-
tunity to present and discuss the results from recently completed and
currently ongoing clinical trials (Figure 1). In total, the results from 15
different clinical trials, ranging from small monocentered pilot studies
to larger multicentered phase 2 trials and involving around 500 patients
across Europe, North America, and Africa, were presented. Here, we
summarize some of the key findings.
In 2005, Kieran et al. [12] reported the results from a clinical study
on the feasibility and efficacy of a four-drug metronomic treatment
regimen, involving continuous oral thalidomide and celecoxib with al-
ternating metronomic etoposide and cyclophosphamide in 20 consec-
utive patients with relapsed, incurable cancer of various tumor types.
Although the disease of eight patients rapidly progressed, suggesting
that metronomic treatments may be more effective in minimal residual
disease setting, 10 patients remained on therapy for a longer period
than their prior remission. Furthermore, three partial responses and
seven stable disease for more than 6 months were observed, leading
to an overall clinical benefit of 50%. After this relative clinical success
and the recent demonstration of the potent antiangiogenic properties
of peroxisome proliferator–activated receptor α agonists [13], fenofi-
brate was added to the subsequent protocol, and the safety and efficacy
of the resulting five-drug metronomic chemotherapy regimen was in-
vestigated in 101 consecutive patients with relapsed, incurable disease
of various tumor types in eight different strata, and results of this com-
bination were presented and are being readied for publication (M.W.K.,
personal communication). The antiangiogenic mechanism of the com-
bination of celecoxib, fenofibrate, and oral etoposide or cyclophospha-
mide has recently been demonstrated in preclinical murine models [14].
Thalidomide is, however, not tested in preclinical murine models be-
cause of differences in metabolism when compared with humans.
An adapted five/six-drug protocol was subsequently investigated by
Peyrl et al. [15] in 13 patients with recurrent embryonal or ependymal
brain tumors. The sophisticated treatment regimen consisted of con-
tinuous oral thalidomide, celecoxib, and fenofibrate with alternating
metronomic etoposide and cyclophosphamide, in combination with bi-
weekly low-dose bevacizumab, with or without intrathecal chemother-
apy (etoposide and/or liposomal cytarabin). Very impressive results were
reported with excellent 2-year event-free survival (EFS) and 3-year over-
all survival (OS) in a study population with a very dismal prognosis.
Following a similar gradual development strategy, during the meet-
ing, Dr Sterba reported on the results and recent evolution of the
COMBAT (Combined Oral Maintenance Biodifferentiating and Anti-
angiogenic Therapy) protocol. The first COMBAT regimen, which
was based on continuous administration of celecoxib in combination
with retinoic acid and alternating metronomic etoposide and temo-
zolomide, was investigated in 22 patients with refractory, relapsing,
or “high risk of relapse” tumors of various types [16]. This study re-
ported a response rate of 32% and a clinical benefit of 77%, with 3
complete response, 4 partial response, and 10 stable disease for more
than 6 months. However, long-term clinical outcome remained dis-
mal, with a 2-year EFS of less than 10% and a 2-year OS of 30%.
In an attempt to increase the long-term efficacy of COMBAT, new
agents were incorporated into the protocol based on preclinical and
clinical findings, including the peroxisome proliferator–activated recep-
tor α agonist fenofibrate, vitamin D (COMBAT II), and anti-VEGF
antibody bevacizumab (COMBAT III). A multicentered clinical trial
was designed to investigate the efficacy of COMBAT II and III in pa-
tients with relapsed or high risk of relapse tumors of various types,
including brain tumors, neuroblastoma, and sarcomas. A total of 81 pa-
tients were recruited across four different institutions in Czech Re-
public, France, and Slovakia. After a median follow-up of 1 year, a
promising response rate was reported (J.S., personal unpublished data).
Interestingly, the efficacy of COMBAT II and III is proving to be su-
perior to the first COMBAT protocol. Surprisingly, an effect of sex
was observed on the clinical outcome, with male patients responding
significantly better than female patients in terms of both EFS and OS.
Finally, nonrandomized retrospective comparison of the subgroup of
patients with relapsed high-grade sarcomas revealed improved overall
survival with metronomic treatment over MTD-based chemother-
apy. This promising result was in accordance with a recent study by
Klingebiel et al. [17] showing that metronomic-based oral mainte-
nance (i.e., daily trophosphamide and etoposide, alternating with daily
trophosphamide and idarubicin) was more effective than high-dose
chemotherapy in children with metastatic soft tissue sarcoma (5-year
OS of 52% and 15%, respectively; P = .001).
The preliminary results of a phase 2 clinical trial of a combination of
weekly vinorelbine and daily cyclophosphamide in recurrent or refrac-
tory pediatric tumors were also presented during the meeting (O.O.,
personal unpublished data). This study, which recruited 114 patients
with rhabdomyosarcoma (RMS), soft tissue sarcoma, bone sarcoma,
neuroblastoma, and medulloblastoma, reported mixed results accord-
ing to the tumor type. For instance, the response rate and clinical ben-
efit for all evaluable patients were 18% and 36%, respectively, whereas
they were 34% and 52%, respectively, in the subgroup of patients
with RMS. The 6-month progression-free survival (PFS) was 28%
and the 1-year OS was 29% for all patients. For RMS patient only,
the 6-month PFS was 40% and the 1-year OS was 34%. This study
thus confirms the results previously reported by Casanova et al. [18,19],
showing that vinorelbine, both alone or in combination with low-dose
metronomic cyclophosphamide, can be effective in the treatment of
recurrent or refractory RMS. On the basis of the results of these pilot
Figure 1. The 2nd International Workshop on Metronomic and Anti-
Angiogenic Chemotherapy in Paediatric Oncology.
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studies, the EpSSG (European Soft Tissue Sarcoma Study Group) is
currently evaluating the benefit of “maintenance chemotherapy” with
the association of vinorelbine and cyclophosphamide for high-risk
RMS patients in a randomized trial.
Results from other pilot, phase 1 and 2 clinical trials, were also
presented during the workshop. Dr Kivivuori presented data from
the AngioComb trial (i.e., antiangiogenic combination therapy for
pediatric tumors in the brainstem) from NOPHO (Nordic Society
of Paediatric Haematology and Oncology). Eight patients with diffuse
intrinsic pontine glioma were treated with a combination of radiother-
apy and the radiosensitizer topotecan, followed by metronomic etopo-
side and thalidomide in combination with celecoxib. Comparison with
eight historic matching control patients revealed that the AngioComb
therapy resulted in a significant benefit in time to clinical progression
(11 vs 6.8 months, P = .04) [20]. Moreover, the OS at 12 months was
63% in this patient population with very poor prognosis. Therapy
was well tolerated in all patients, with very few toxic adverse effects
except for neutropenia, and resulted in a significant improvement in
the quality of life. A total of 24 patients have now been enrolled in an
expanded study across the different NOPHO countries (i.e., Finland,
Sweden, Norway, Denmark and Iceland), and there are plans also to
extend AngioComb therapy to other pediatric malignancies, including
glioblastoma multiform and ependymoma.
Dr Baruchel presented the results of several pilot and phase 1 phar-
macokinetic studies of metronomic chemotherapy [21–23] and anti-
angiogenic therapy [24] in pediatric patients with recurrent and/or
refractory tumor of various types. Although the results of these studies
were quite disappointing in terms of clinical response, they provided
essential pharmacokinetic data for some of the main anticancer agents
currently used in metronomic and antiangiogenic treatments in chil-
dren (i.e., celecoxib, vinblastine, cyclophosphamide, temozolomide,
and bevacizumab) and investigated numerous potential biomarkers
to monitor treatment activity (see section o Biomarker). Elsewhere,
safety results were reported for the ongoing New Approaches to
Neuroblastoma Therapy’s (NANT’s) clinical trial of low-dose metro-
nomic cyclophosphamide in combination with the biphosphonate,
zoledronic acid, in children with recurrent or refractory neuroblas-
toma. Treatment was well tolerated with only few toxic adverse effects,
and clinical and biologic responses were observed [25]. The prelimi-
nary data of a phase 1 study organized by the Children’s Oncology
Group (COG) also showed the feasibility of combining metronomic
vinblastine and celecoxib to standard therapy for the treatment of
Ewing sarcoma patients, with only three dose-limiting toxicities re-
ported (J.L. Felgenhauer and S.B., personal unpublished data).
Finally, the preliminary results of the first pilot study of metronomic
chemotherapy performed in Africa were also presented during the
meeting [26]. In low- and middle-income countries, although the real
incidence of cancer remains unknown due to the lack of accurate can-
cer registers and very poor survival rates, it is estimated that around
200,000 children are diagnosed with cancer each year and only approx-
imately 25% survive [27]. Several issues prevent the development of an
efficient management of children with cancer in developing countries:
the availability of drugs and treatment facilities, delayed diagnosis, cost,
lack of follow-up, compliance with treatment, prior consultation of tra-
ditional practitioners, and cultural barrier. The management of children
with relapsed, progressive, and/or very advanced disease is particularly
challenging in these countries because second-line intensive or experi-
mental treatments with new expensive drugs are not realistic options.
Therefore, metronomic chemotherapy regimens, based on inexpensive
off-patent anticancer drugs administered orally, in an outpatient basis,
represent a genuine alternative strategy for children with cancer in low-
income countries. The efficacy of a metronomic protocol, consisting of
weekly vincristine, daily low-dose cyclophosphamide, and twice-weekly
methotrexate, was evaluated in a small prospective study performed in
Mali (Metro-Mali-01) in the Bamako Center, which is part of the
French-African Group of Paediatric Oncology [26]. Twelve children
with relapsing or refractory nephroblastoma, retinoblastoma, or neuro-
blastoma were enrolled in the study. Treatment was well tolerated with
no grade 3 and only two grade 4 (anemia and neutropenia) toxicities
reported. The best response was disease stabilization observed in seven
patients (58%), including three patients for more than 6 months after
treatment completion, and after a median follow-up of 39 weeks, six
patients (50%) were alive. This pilot study demonstrates that metro-
nomic chemotherapy can be delivered at low cost, with minimal toxic-
ity, and can be efficacious in children and young adults with cancer and
provides a strong rationale for the rapid development of further clinical
trials in middle- and low-income countries [28].
Upcoming Clinical Trials
During the meeting, it was also noted that numerous clinical trials
of metronomic and/or antiangiogenic therapy in pediatric cancer pa-
tients are currently ongoing across Europe, North America, and South
America. In addition to the ongoing clinical trials detailed above (i.e.,
COMBAT II and III, CCLG-EpSSG-RMS-2005, AngioComb), the
clinical studies whose results are most anticipated include
– the NANT 2007-02 study investigating the toxicity and feasi-
bility of the combination of chemoswitch cyclophosphamide (i.e.,
28-day cycles of high-dose cyclophosphamide on day 1 followed
by continuous low-dose cyclophosphamide) and zoledronic acid,
with and without bevacizumab, in children with refractory or
recurrent high-risk neuroblastoma
– the SFCE-Metro-01 (French Society for Childhood Cancer)
phase 2 trial of low-dose metronomic cyclophosphamide alternat-
ing with low-dose methotrexate and in combination with contin-
uous celecoxib and weekly vinblastine in children and young
adults with relapsed or refractory solid tumors (NCT01285817)
– the Metro-Mali-02 (French-African Group of Paediatric On-
cology) phase 2 trial of daily low-dose cyclophosphamide in com-
bination with valproic acid, weekly vincristine, and twice-weekly
methotrexate for the treatment of relapsing or refractory pediatric
solid tumors
– the GLATO 2006 (Latin-American Group for the Treatment
of Osteosarcoma) randomized phase 3 trial investigating the effi-
cacy of metronomic cyclophosphamide and methotrexate in
combination with conventional chemotherapy and surgery in
metastatic osteosarcoma patients
– the randomized phase 2 trial of bevacizumab in combination
with standard chemotherapy in children and adolescents with
metastatic RMS and other soft tissue sarcoma (NCT00643565)
– the pilot study of bevacizumab in combination with radio-
therapy and temozolomide in children and young adults with
newly diagnosed high-grade glioma and diffuse intrinsic pon-
tine glioma (NCT00890786)
– the phase 1 study of bevacizumab and sorafenib in combina-
tion with low-dose cyclophosphamide in children and young
adults with refractory solid tumors and leukemia performed at
the St Jude Children’s Research Hospital (Memphis, TN).
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Results from the Metronomic Working Groups
With the assembly of experts in metronomic therapy at the 2nd In-
ternational Workshop, a number of participants met separately to in-
vestigate the possible development of an international protocol for the
treatment of specific tumor types. Three working groups were consti-
tuted to propose a protocol for the treatment of brain tumors, neuro-
blastoma, and sarcomas.
The brain tumor committee had a number of different proposals
including those for ependymoma, brainstem glioma, and medulloblas-
toma. After extensive discussion and preliminary feasibility assessment,
plans for a recurrent medulloblastoma protocol were approved in prin-
ciple (Figure 2). Members of this ad hoc committee followed up by
e-mail and conference calls to fine-tune the protocol proposal. Approx-
imately 20 centers throughout Europe and the United States have
been identified for participation. Ethical approval has been obtained
in Austria with plans to begin accrual in approximately 6 months.
Similarly, the neuroblastoma and sarcoma committees developed
different proposals based on recent clinical data and sound preclinical
rationale. After extensive discussions to assess feasibility and anticipate
potential toxicities, a metronomic treatment protocol for recurrent
neuroblastoma patients was approved in principle. This proposal will
be finalized in the next few months and regulatory approval and fund-
ing application processes will be initiated.
Future Challenges
Terminology
In the original publication from Browder et al. [2], the regimen
consisting of weekly administration of cyclophosphamide was termed
antiangiogenic scheduling as angiogenesis inhibition was shown to be re-
sponsible for the observed antitumor effect. Soon after, Hanahan et al.
[4] coined the term metronomic to the concept of antiangiogenic
chemotherapy. Nevertheless, as foreseen by Hanahan et al. [4] and
Gasparini [29], the important finding behind low-dose antiangiogenic
chemotherapy was very likely to be the new schedule of drug admin-
istration [28]. Although metronomic and/or antiangiogenic chemo-
therapy remain the preferred terminology, it does not always reflect
the underlying mechanisms of action or the complexity of the treat-
ment regimens. In several metronomic studies, nonchemotherapeutic
drugs per se such as thalidomide, Cox-2 inhibitors, retinoic acid, and,
more recently, fenofibrate or zoledronic acid have been used in com-
bination with conventional chemotherapeutic drugs, making the term
chemotherapy not perfectly adapted to these combinatorial strategies. In
addition, recent findings have shown that the anticancer activity of
metronomic chemotherapy does not solely rely on antiangiogenic ef-
fects. Instead, this type of treatment may represent a form of multi-
targeted therapeutic strategy [5,30], making the term antiangiogenic
therapy probably too restrictive. It is also important to realize that
not all chemotherapeutic agents administered in a long-term, repetitive,
oral manner will have an antiangiogenic mechanism of action, despite
the frequent use of this terminology. Lastly, nonchemotherapeutic
drugs used in metronomic protocols are sometimes administered at
higher doses than when used for nonanticancer purposes. This is, for
instance, the case with Cox inhibitors [12,16,21,31], retinoic acid [16],
and fluvastatin [32]. Thus, the term low dose is not always appropriate
either. In the case of complex multimodal metronomic protocols, we
recommend to use broader terms such as metronomic treatment or
metronomic scheduling of anticancer treatment (MSAT) [30].
Anticipating Long-term Toxicities
In all the different clinical trials discussed during the meeting, pre-
dominantly mild toxicities were reported. The most common adverse
effects observed were hematological toxicities, such as neutropenia,
lymphopenia, and anemia, and were usually grade 1 or 2. As expected,
adverse events were more frequent when numerous drugs were com-
bined and episodes of peripheral neuropathy, anorexia, ataxia, fatigue,
and infections were encountered (M.W.K. and A.P., personal unpub-
lished observation).
Although normal growth and development was maintained in chil-
dren who were treated with alternating metronomic etoposide and cy-
clophosphamide in combination with continuous oral thalidomide
and celecoxib for up to 2 years [12] and despite the overall good tol-
erance of metronomic chemotherapy in children, potential long-term
toxicities still warrant caution and require further investigations. It is
Figure 2. Metronomic multitarget antiangiogenic protocol for relapsing medulloblastoma.
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important to note, for instance, the high incidence of secondary leu-
kemia that has been reported after frequent intravenous etoposide
administration in children and young adults [33], requiring careful ob-
servation in patients treated with the oral formulation for extended
periods. In addition, deleterious effects of cyclophosphamide on sper-
matogenesis have been recently reported [34]. Although investigat-
ing the effects of MTD-based chemotherapy, this study showed that
ifosfamide was associated with a lower risk of gonadal damage than
cyclophosphamide, suggesting that ifosfamide may be a safer drug to
use in metronomic treatments. Finally, potential radiosensitization is-
sues as evidenced by episodes of hemorrhagic cystitis and radiation
pneumonitis have also been noted in the ongoing COG study of
metronomic vinblastine and celecoxib in combination with standard
therapy in children with Ewing sarcoma (J.L. Felgenhauer and S.B.,
personal unpublished data).
Elsewhere, recent evidence shows that the administration of certain
anticancer agents, including chemotherapeutics, vascular-disrupting
agents, and antiangiogenic drugs, can induce rapid systemic elevation
in circulating endothelial progenitor cells (EPCs). These cells home to
the treated tumor site and can induce angiogenesis and subsequent
tumor cell repopulation and tumor regrowth [35,36]. These host ef-
fects, which were documented in both non–tumor-bearing and tumor-
bearing mice after treatment with anticancer drugs can compromise
some of the antitumor effects of the drug used [35,36]. The combina-
tion of antiangiogenic drugs, and to some extent metronomic chemo-
therapy, with the anticancer agents that induced rapid systemic host
effects resulted in a reduction in tumor cell repopulation, thus prevent-
ing tumor regrowth [36–38]. However, it is important to note that, in
addition to cytotoxic drugs, some antiangiogenic agents can also
induce systemic host responses. It has been demonstrated that the ad-
ministration of escalating doses of the receptor tyrosine kinase inhib-
itor, sunitinib malate, to non–tumor-bearing mice resulted in elevated
plasma levels of multiple growth factors, cytokines, and chemokines
(e.g., G-CSF, SDF-1) [39]. These effects could explain the provocative
results of preclinical studies, which demonstrated that tumor invasive-
ness and metastasis are being promoted by both tumor and host cells
in response to treatment with certain antiangiogenic drugs [40,41]. In-
terestingly, it is plausible that such responses may be minimal or ab-
sent when using low-dose metronomic chemotherapy (Y.S., personal
communication). However, these systemic effects need to be further
investigated in the context of combinatorial metronomic treatments
to anticipate any potential long-term adverse effects.
Biomarker
One of the major limitations of metronomic treatments is empiri-
cism. Powerful and reliable biomarkers (i.e., diagnostic, predictive,
and surrogate markers) are crucially needed to predict which patients
are most likely to benefit from MSAT and to monitor treatment ac-
tivity. Furthermore, the complex mechanisms of action of the differ-
ent agents used in combination still need to be completely unraveled
to define the best drugs to use according to the clinical setting, tumor
type, and patient population.
Considerable efforts have been made recently, both at the preclini-
cal and clinical level, to try and identify markers of activity for metro-
nomic chemotherapy and antiangiogenic therapies. The first obvious
candidates are serum levels of proangiogenic and antiangiogenic
growth factors and cytokines, although their predictive potential has
been poorly investigated in pediatric cancer patients to date. During
the meeting, Dr Baruchel presented the results of pharmacodynamic
analyses performed in several completed and ongoing phase 1 trials of
metronomic chemotherapy in children with relapsed or refractory tu-
mors. No significant change in serum levels of VEGF, basic fibroblast
growth factor, soluble Vascular Cell Adhesion Protein 1 (sVCAM-1),
thrombospondin-1 (TSP-1), and endostatin were observed in pediatric
patients treated with low-dose metronomic vinblastine or cyclophos-
phamide in combination with celecoxib [21]. In a recent multicenter
pilot study, a trend toward a greater decrease in VEGF plasma levels
associated with longer EFS was observed in pediatric patients with recur-
rent brain tumors treated with low-dose metronomic temozolomide
[23]. In the four-drug antiangiogenic clinical trial of thalidomide, cele-
coxib, oral etoposide, and oral cyclophosphamide, elevated thrombo-
spondin levels at baseline were correlated with event-free survival [12],
and a similar analysis of the five-drug strategy is underway (M.W.K.,
personal communication).
After robust preclinical studies by Bertolini, Shaked, and others (re-
viewed in Bertolini et al. [42] and Pasquier and Dias [43]), circulating
endothelial cells (CECs) and EPC have emerged as promising surro-
gate markers to monitor the activity of metronomic chemotherapy and
antiangiogenic therapies. In mice, suppressed levels of viable EPCs
have been shown to correlate with the optimal biologic dose of anti-
angiogenic drugs or metronomic antiangiogenic treatment strategy
[44,45]. In clinical studies, breast cancer patients treated with metro-
nomic cyclophosphamide and thalidomide-increased levels of apopto-
tic CECs were reported, but only in patients responding to the therapy
[46]. In addition, in breast cancer patients treated with metronomic
chemotherapy and bevacizumab, higher baseline CEC levels were
associated with clinical response and improved PFS [47,48]. Although
a significant correlation between apoptotic CECs and clinical out-
come has been recently reported in children treated with bevacizumab
[24], the pediatric clinical data addressing the predictive value of CECs
and EPCs remain sparse. These cells are currently under evaluation in
numerous COG phase 1 studies of various metronomic and antiangio-
genic treatments including sunitinib, sorafenib, pazopanib, metronomic
etoposide, and bevacuzimab in combination with metronomic chemo-
therapy. Similarly, future clinical trials will need to include more bio-
logic investigations to validate these potential predictive and surrogate
markers to better monitor metronomic treatments.
Mechanisms of Action
Another issue fueling the empiricism associated with these treat-
ments is the lack of complete understanding of the mechanisms of ac-
tion. During the past decade, sustained research efforts have helped
decipher the different mechanisms involved in the activity of antian-
giogenic therapies: i) normalization of tumor vasculature that may im-
prove drug delivery and efficacy of radiotherapy, ii) prevention of rapid
tumor cell repopulation after MTD-based chemotherapy, and iii) po-
tentiation of the antivascular activity of chemotherapy [49,50]. Simi-
lar in-depth biologic studies are now needed to unravel the complex
mechanisms of action of metronomic treatments. During the meeting,
it was suggested to try and implement state-of-the-art imaging technol-
ogies, such as dynamic contrast-enhanced magnetic resonance im-
aging, in clinical trials to investigate potential changes in blood flow
and tumor perfusion during metronomic treatment. Additional mech-
anisms recently unveiled were also thoroughly discussed. These include
restimulation of the anticancer immune response [51], direct effects on
cancer cells [52–54], and potential induction of senescence in vascular
endothelial cells (E.P., personal unpublished data). Given the combi-
natorial aspect of metronomic chemotherapy regimens, it is most likely
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that more mechanisms are yet to be discovered, thus calling for further
studies. For instance, the recent demonstration of the key role played
by putative cancer stem cells in the establishment of the tumor vascu-
lature [55] warrants the investigation of the effects of metronomic che-
motherapy on cancer stem cells.
Rational Design of Clinical Trials and Relevant End Points
Several questions still need to be addressed to help design optimal
clinical trials. Numerous anticancer drugs fit the requirements that de-
fine a potential candidate for metronomic treatments: i) orally avail-
able, ii) nonoverlapping and low toxicity, iii) antiangiogenic and/or
immunostimulant properties, and iv) low probability of inducing drug
resistance (Table 1). Similarly, numerous types of high-risk tumors,
including brain tumors (i.e., high-grade glioma, ependymoma, medul-
loblastoma), neuroblastoma, and sarcomas, could potentially benefit
from these treatments. As discussed previously, the common utiliza-
tion of daily oral therapy for the maintenance phase of leukemia
may represent an old example of metronomic chemotherapy. How-
ever, strong rationales are still needed to determine the best drug candi-
dates and drug combinations according to the tumor type and clinical
setting. In the ongoing clinical trial in high-risk RMS patients, for
instance, cyclophosphamide was chosen to be combined with vinorel-
bine, based on i) its proven activity in RMS, ii) its bioavailability when
given by mouth allowing low-dose continuous administration on an
outpatient basis, and iii) its documented efficacy when used at low
dose in other clinical settings.
Elsewhere, the best treatment end points remain to be determined
to fully appreciate the potential clinical benefits of metronomic treat-
ments. This again depends on the clinical setting. In phase 2 trials,
response rates and 6-month EFS are still the most commonly used
end points. However, it is increasingly accepted that the Response
Evaluation Criteria in Solid Tumors (RECIST) may not be well suited
for the evaluation of metronomic and antiangiogenic treatments. Fur-
thermore, the capacity of metronomic chemotherapy to induce disease
stabilization, associated with a good quality of life, is to be regarded as
a desirable and relevant clinical end point. This is particularly the case
in maintenance and palliative care settings. Therefore, an effort should
be made to develop reliable methods to objectively assess the impact of
these treatments on patient quality of life. Duration of clinical benefit
compared to previous treatments may also be included to assess the
efficacy of these treatments. Finally, it should be noted that time to
best response is usually longer with metronomic versus conventional
treatments, thus suggesting that later assessments of clinical end points
may be preferable.
When and how to stop metronomic therapy also represents a crucial
issue that needs to be addressed. The long median time to response
suggests that treatment should not be terminated too early, even in
the absence of objective clinical response. Furthermore, a recent case
report of rapid and fatal relapse soon after treatment completion also
warrants caution as to when to discontinue therapy in children who
achieved remission after long-term metronomic treatment [56]. The
best strategy regarding time to stop therapy remains to be determined
for each tumor type and clinical setting. Should long-term metronomic
treatments be stopped abruptly? Or inversely, should it be stopped
gradually through de-escalation strategy? Future preclinical studies
and clinical trials will need to address these questions.
Key Messages from the Meeting
Metronomic treatments constitute an alternative strategy that is gain-
ing increasing interest in both adult and pediatric oncology. It repre-
sents a promising therapeutic option particularly in patients with
high-risk refractory and/or relapsed cancer as well as in heavily pre-
treated patient populations. Although complete responses remain
rare, these treatments often lead to long-term disease stabilization
and significant improvement of the quality of life of patients. Despite
recent clinical success in adults [5], the implementation of metro-
nomic treatments in pediatric oncology is still in its early stage as a
result of the lack of state-of-the-art clinical studies clearly demonstrat-
ing efficacy. Strong international clinical and biologic collaborations
are therefore needed to facilitate the development of metronomic
scheduling to treat children with cancer, and these international meet-
ings have become an important venue for bringing a diverse array of
experts together to address these problems. With the next meeting
planned for 2012 in Israel, we have the opportunity to begin to sys-
tematically evaluate this treatment modality in pediatric patients.
One of the main limitations in this field is the current lack of pow-
erful and reliable biomarkers to overcome the empiricism associated
with the design of treatment regimens and clinical trial protocols.
Future biologic investigations will need to use more relevant models
and tools, integrating cutting-edge technologies. These may include
advanced imaging technology to better understand the effects of met-
ronomic treatments on blood flow and tumor perfusion, state-of-the-
art flow cytometry to detect and quantify bone marrow–derived and
other circulating proangiogenic cells, ELISA and multiplex cytokine
assays to identify markers of activity, and pharmacogenomics and
proteomic analyses to perform molecular profiling and predict treat-
ment response and clinical outcome. In addition, innovative preclin-
ical models taking into account tumor heterogeneity, as well as the
contribution of tumor stroma and cancer stem cells, are also crucially
needed. Finally, large multicentered clinical studies, integrating bio-
marker analyses, will need to investigate and validate the best treat-
ment combinations for each tumor type and patient population.
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Table 1. Drugs That Can Be Used in MSAT.
Chemotherapeutic Drugs Nonchemotherapeutic Drugs
Alkylating agents Anti-VEGF agents
Cyclophosphamide Bevacizumab
Temozolomide Cox inhibitors
Trophosphamide Celecoxib
Ifosfamide HDAC inhibitors
Antimetabolites Valproic acid
Methotrexate Tyrosine kinase inhibitors
Antimicrotubule agents Sunitinib
Vinblastine Sorafenib
Vinorelbine Imatinib
Vincristine Dasatinib
Anthracyclines Nilotinib
Idarubicin Others
Topoisomerase inhibitors Fenofibrate
Etoposide Fluvastatin
Topotecan Retinoic acid
Thalidomide
Zoledronic acid
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